Autopsy report · NCT05212701

To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer

“Dompé decided to withdraw the study due to the numerous difficulties encountered in enrollment, mainly due to the rapidly and continuously changing oncology drug scenario . No patients were enrolled.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Dompé Farmaceutici S.p.A

Sponsor type

Industry

Conditions

Fatigue; Locally Advanced or Metastatic Breast Cancer

Interventions

Reparixin; Placebo

Participants

0

Sites

20

Countries

Germany, Italy, United States

Trials that died the same way

• Crossover Evaluation of Effect of Atorvastatin on PK of Irinotecan in CRC Patients Receiving FOLFIRI
  “Study was withdrawn due to lack of patient enrollment.” (73% match in meaning)
• One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease
  “The study was terminated early due to difficulty in enrollment and lack of clinical study drug access.” (70% match in meaning)
• Effectiveness and Safety of Early Treatment With Infliximab for Hip Arthritis Associated With Ankylosing Spondylitis (AS) (P06451)
  “No patient enrolled after 6 months from the start. The decision to withdraw the study was based on a feasibility reevaluation conducted with investigators.” (70% match in meaning)
• Ozurdex Monotherapy Trial
  “The study was withdrawn due to insufficient participant enrollment.” (69% match in meaning)
• Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma
  “This study was terminated early due to manufacturer withdrawal of support (study medication) due to lack of enrollment.” (68% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.